Business Context and Reporting Period
This Form 8-K is filed by Imprimis Pharmaceuticals, Inc. (the "Company") on June 16, 2017, reporting events occurring between May 1, 2017, and June 20, 2017. The filing details the Company's strategic separation of specific assets into its previously wholly-owned subsidiary, Eton Pharmaceuticals, Inc. ("Eton"), and Eton's subsequent capital raise.
Key Financial Metrics and Agreements
- Capital Raise: Eton raised approximately $20,000,000 in gross proceeds (net proceeds approx. $18,000,000) through a Series A Preferred Stock offering.
- Ownership Stake: Following the Series A Round, the Company retains 3,500,000 shares of Eton common stock, representing approximately 27% of Eton's equity and voting interests.
- Revenue Rights (Royalties): Eton must pay the Company a royalty of 6% of net sales of licensed products while patents are outstanding, reducing to 3% thereafter.
- Milestone Payments: Eton is obligated to pay $50,000 to the Company upon initial patent issuance for each licensed product.
- Management Services: Under a Management Services Agreement (MSA), Eton pays the Company $10,000 per month for administrative support.
- Debt/Liquidity: The filing does not provide specific balance sheet data for the Company's overall liquidity or debt levels, focusing instead on the transaction terms.
Material Changes and Transactions
On May 9, 2017, the Company entered into Asset Purchase and License Agreements with Eton, transferring intellectual property rights for synthetic corticotropin and injectable pentoxifylline. These agreements were conditioned on Eton raising at least $10,000,000, a threshold met by the June 2017 Series A Round. Additionally, the Company and Eton executed an MSA on May 1, 2017, to facilitate operational transition.
Outlook, Risks, and Management Commentary
- Future Obligations: Eton is required to file a Form S-1 registration statement within nine months of the closing and complete an IPO by December 31, 2018, subject to extension by Series A holders.
- Stock Terms: Series A Stock converts to common stock at a price between $2.25 and $3.00 per share, carries a 6% annual dividend, and holds liquidation preference over other equity.
- Management Transition: The Company's CEO and CFO currently serve as directors of Eton. The CFO is expected to resign from the Eton board within six months. Eleven Company employees have entered consulting agreements with Eton to assist operations until Eton hires its own management.
- Risks: The MSA is terminable by either party upon written notice. The Series A dividend is subject to change in the event of default.
Investor Verification Checklist
- Verify the final closing date and total net proceeds of the Series A Round (initial closing June 19, 2017; additional closing expected June 26, 2017).
- Confirm the exact conversion price of Series A Stock once subsequent financing conditions are resolved.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for detailed terms of the License Agreements and MSA.
- Monitor Eton's progress toward filing the Form S-1 registration statement within the required nine-month window.
- Assess the impact of the 27% retained equity stake on the Company's future consolidated financial reporting.